You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
CGI will provide target identification and biomarker discovery services for three cancer drugs that BeiGene is currently developing.
The firm saw a 204 percent increase in clinical services test volume year over year driven by increased offerings in several testing services.
The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.
The partners said they will also combine their respective expertise to offer pharmaceutical companies help in developing companion diagnostics for oncology.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The company said it plans to use the proceeds of the offering for general corporate purposes.
The firm said its Focus::Myeloid NGS-based panel for myeloid malignancies provides information for diagnosis, prognosis, treatment, and risk stratification of patients.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.